Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
Refine your Search
|
Title
|
Publication Date
|
Price
|
Relevance
|
Dainippon Sumitomo Pharma Co., Ltd. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
100% |
XOMA Ltd. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
99% |
Hypertension - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
96% |
Infertility - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
96% |
Insomnia Therapeutics
Pipeline Assessment and Market Forecasts to 2018
|
Dec 2011 |
£2,215 |
93% |
Type 2 Diabetes - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
93% |
LG Life Sciences, Ltd – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
92% |
|
Anemia Drugs
|
Apr 2010 |
£2,500 |
92% |
Diabetic Neuropathy Therapeutics
Pipeline Assessment and Market Forecasts to 2017
|
Mar 2011 |
£1,265 |
91% |
Kyowa Hakko Kirin Co., Ltd. – Product Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
91% |
Myocardial Infarction - Pipeline Review
Q3 2011
|
Jul 2011 |
£315 |
89% |
|
Acute Coronary Syndrome
|
Apr 2010 |
£2,180 |
88% |
Esophagitis - Pipeline Review
H2 2011
|
Nov 2011 |
£315 |
88% |
Diabetes - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
88% |
Insomnia - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
88% |
Endometriosis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
87% |
Colorectal Cancer - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
87% |
|
Anti-Hypertensive Drugs
|
Feb 2010 |
£2,500 |
86% |
Ovarian Cancer - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
86% |
Chronic Lymphocytic Leukemia (CLL) - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
86% |
Multiple Myeloma (Kahler's Disease) - Pipeline Review
H1 2012
|
Jan 2012 |
£325 |
86% |
Multiple Sclerosis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
86% |
Diabetic Neuropathy - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
85% |
Hypertension - Pipeline Review
Q1 2011
|
Feb 2011 |
£315 |
85% |
Ulcerative Colitis - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
85% |
Non-Small Cell Lung Cancer - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
85% |
Obesity - Pipeline Review
H2 2011
|
Sep 2011 |
£315 |
85% |
Chronic Myelocytic Leukemia (CML) - Pipeline Review
H2 2011
|
Oct 2011 |
£315 |
85% |
|
Inflammatory Bowel Disease Therapeutics
|
Apr 2010 |
£2,500 |
85% |
|
Cardiovascular Drugs
|
Apr 2010 |
£2,815 |
85% |
